<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pentobarbital: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pentobarbital: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Pentobarbital: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9754" href="/d/html/9754.html" rel="external">see "Pentobarbital: Drug information"</a> and <a class="drug drug_patient" data-topicid="10963" href="/d/html/10963.html" rel="external">see "Pentobarbital: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F208174"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Nembutal [DSC]</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1054820"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antiseizure Agent, Barbiturate</span>;</li>
<li>
<span class="list-set-name">Barbiturate</span>;</li>
<li>
<span class="list-set-name">General Anesthetic</span>;</li>
<li>
<span class="list-set-name">Hypnotic</span>;</li>
<li>
<span class="list-set-name">Sedative</span></li></ul></div>
<div class="block dop drugH1Div" id="F208190"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Adjust dose based on patient's age, weight, kidney and liver function, and medical condition. Consider the potential for delayed metabolism or elimination in infants &lt;6 months of age (Krauss 2006).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4c810afd-01bd-4651-a7d0-8e6e62fa9dec">Hypnotic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypnotic: </b>
<b>Note:</b> Use has generally been replaced by other agents.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IM: 2 to 6 mg/kg/dose; maximum dose: 100 mg/dose.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="72873dff-bb0a-4144-9fec-01b37666fe14">Preoperative sedation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Preoperative sedation:</b>
<b>Note</b>: Use has generally been replaced by other agents.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">IM: 2 to 6 mg/kg/dose; maximum dose: 100 mg/dose (Krauss 2006; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:6em;">IV: 1 to 3 mg/kg/dose every 10 minutes up to a maximum <b>total</b> dose of 6 mg/kg, not to exceed <b>total</b> dose of 100 mg (Coté 2013; Coté 2019; manufacturer's labeling).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e957755b-7e6a-4c47-abc7-399e245a30c5">Procedural sedation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Procedural sedation: Note:</b> Use has generally been replaced by other agents.</p>
<p style="text-indent:-2em;margin-left:4em;">IM: Infants, Children, and Adolescents: IM: 2 to 6 mg/kg; maximum dose: 100 mg/dose (Krauss 2006).</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Infants, Children, and Adolescents: IV: Initial: 1 to 2 mg/kg/dose; additional doses of 1 to 2 mg/kg every 3 to 5 minutes to desired effect; usual effective <b>total</b> dose: 1 to 6 mg/kg; maximum <b>total</b> dose: 100 mg (Krauss 2006; Mason 2004). <b>Note:</b> Patients receiving concurrent barbiturate therapy may require higher total mg/kg doses (up to 9 mg/kg) (Mason 2004).</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Limited data available:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants: Oral: Initial: 4 mg/kg/dose; if needed, may administer supplemental doses of 2 to 4 mg/kg/dose every 30 minutes; maximum <b>total</b> dose: 8 mg/kg (Mason 2004).</p>
<p style="text-indent:-2em;margin-left:6em;">Children &lt;4 years: Oral: 3 to 6 mg/kg/dose; maximum dose: 100 mg/dose (Krauss 2006).</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥4 years and Adolescents: Oral: 1.5 to 3 mg/kg/dose; maximum dose: 100 mg/dose (Krauss 2006).</p>
<p style="text-indent:-2em;margin-left:4em;">Rectal: Limited data available:</p>
<p style="text-indent:-2em;margin-left:6em;">Children &lt;4 years: Rectal: 3 to 6 mg/kg/dose; maximum dose: 100 mg/dose (Krauss 2006).</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥4 years and Adolescents: Rectal: 1.5 to 3 mg/kg/dose; maximum dose: 100 mg/dose (Krauss 2006).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="627230c8-9b7a-477b-b733-ca38e8045b5a">Reduction of elevated intracranial pressure</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Reduction of elevated intracranial pressure (ICP):</b> Limited data available: <b>Note:</b> Intubation is required; adjust dose based on hemodynamics, ICP, cerebral perfusion pressure, and EEG; continuous arterial blood pressure monitoring and cardiovascular support are recommended (BTF [Kochanek 2019]).</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: <b>Note:</b> Reserve higher doses for use in patients with refractory intracranial hypertension (BTF [Kochanek 2019]).</p>
<p style="text-indent:-2em;margin-left:6em;">Bolus dose: IV: 5 to 10 mg/kg over 20 to 30 minutes; may repeat 5 mg/kg as needed based on clinical response and clinical target (Adelson 2003; Mazzola 2002; Rangel-Castilla 2008; Shein 2016).</p>
<p style="text-indent:-2em;margin-left:6em;">Continuous IV infusion: Initial: 1 mg/kg/<b>hour</b>; adjust to maintain burst suppression on EEG; maintenance dose range: 1 to 2 mg/kg/<b>hour</b> (Adelson 2003; Rangel-Castilla 2008).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="95f9d5ff-f948-4e11-bc30-70a30ca6cac1">Sedation of mechanically ventilated ICU patient</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sedation of mechanically ventilated ICU patient (alternative agent):</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV: Loading dose: 1 mg/kg followed by a continuous IV infusion of 1 mg/kg/<b>hour</b>. Additional boluses at a dose equal to hourly rate may be given every 2 hours as needed. If ≥4 to 6 boluses are administered within 24 hours, then increase maintenance rate by 1 mg/kg/<b>hour</b>; reported required range: 1 to 6 mg/kg/<b>hour</b> (median: 2 mg/kg/<b>hour</b>). Tapering of dose and/or conversion to oral phenobarbital has been reported for therapy ≥5 days (Tobias 1995; Tobias 2000a; Tobias 2000b). <b>Note:</b> Higher rates of adverse effects were observed in a small report that used higher loading and initial maintenance doses (Yanay 2004).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="35f404a1-13f0-458b-903c-16aae02db63a">Status epilepticus refractory to standard therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Status epilepticus refractory to standard therapy: Note:</b> Mechanical ventilation and cardiovascular monitoring required; monitor blood pressure and respiratory rate; titrate dose to cessation of electrographic seizures or burst suppression (AES [Glauser 2016]; NCS [Brophy 2012]).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Loading dose: IV: Usual dose: 5 mg/kg; doses up to 15 mg/kg have been described; administration &gt;50 mg/minute is not recommended (NCS [Brophy 2012]).</p>
<p style="text-indent:-2em;margin-left:6em;">Continuous IV infusion: Initial: 0.5 to 1 mg/kg/<b>hour</b>; may increase up to 5 mg/kg/<b>hour</b>; maintain burst suppression on EEG for 24 to 48 hours (no seizure activity); if the patient experiences breakthrough status epilepticus while on continuous infusion, administer an additional 5 mg/kg bolus and increase infusion rate by 0.5 to 1 mg/kg/<b>hour</b> every 12 hours until burst suppression (Abend 2008; Holmes 1999; Kim 2001; NCS [Brophy 2012]). <b>Note: </b>Withdraw gradually to prevent withdrawal seizures (Holmes 1999; Kim 2001; NCS [Brophy 2012]).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51152578"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. However, a reduced dosage is recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> A risk of propylene glycol toxicity exists in patients receiving pentobarbital, especially in patients with renal impairment; monitor closely (eg, osmolar gap) if using for prolonged periods of time or at high doses (Miller 2008; Pillai 2014).</p></div>
<div class="block dohp drugH1Div" id="F51152579"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. However, a reduced dosage is recommended.</p></div>
<div class="block doa drugH1Div" id="F208178"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9754" href="/d/html/9754.html" rel="external">see "Pentobarbital: Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Adjust dose based on patient's age, weight, and condition.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6073993f-d015-4bee-956f-7b3afb2accfc">Sedative/preanesthesia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sedative/preanesthesia:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM:</b> 150 to 200 mg, as a single dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Initial: 100 mg; if needed, may administer additional increments after at least 1 minute, up to a total dose of 200 to 500 mg.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3bdc9ea7-289f-4752-8056-e3eef3f779c9">Seizures</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Seizures:</b>
<b>IV: Note:</b> Mechanical ventilation and cardiovascular monitoring required; titrate dose to cessation of electrographic seizures or burst suppression (NCS [Brophy 2012]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Neurocritical Care Society recommendations</i> (NCS [Brophy 2012]):</p>
<p style="text-indent:-2em;margin-left:6em;">Loading dose: 5 to 15 mg/kg administered at a rate of ≤50 mg/minute, may give additional 5 to 10 mg/kg; follow with a continuous infusion.</p>
<p style="text-indent:-2em;margin-left:6em;">Continuous infusion: 0.5 to 5 mg/kg/hour. If the patient experiences breakthrough status epilepticus while on continuous infusion, administer an additional 5 mg/kg bolus and increase infusion rate by 0.5 to 1 mg/kg/hour every 12 hours. <b>Note:</b> A period of at least 24 to 48 hours of electrographic control is recommended prior to withdrawing the continuous infusion; withdraw gradually to prevent recurrent status epilepticus.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="83deb875-5abd-4204-9c8d-4dcd7a202c29">Barbiturate coma in severe brain injury patients/elevated intracranial pressure</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Barbiturate coma in severe brain injury patients/elevated intracranial pressure (off-label use):</b>
<b>IV:</b> Loading dose: 10 mg/kg given over 30 minutes (or ≤25 mg/minute), followed by 5 mg/kg every hour for 3 doses; monitor blood pressure and respiratory rate. Maintenance infusion: Initial: 1 mg/kg/hour; may increase to 2 to 4 mg/kg/hour; maintain burst suppression on EEG (Censullo 2003; Eisenberg 1988).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990689"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling. However, a reduced dosage is recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> A risk of propylene glycol toxicity exists in patients receiving pentobarbital, especially in patients with renal impairment; monitor closely (eg, osmolal gap) if using for prolonged periods of time or at high doses (Miller 2008; Pillai 2014).</p></div>
<div class="block doha drugH1Div" id="F50987991"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling. However, a reduced dosage is recommended.</p></div>
<div class="block adr drugH1Div" id="F208143"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:0em;">Frequency not defined.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular: Bradycardia, hypotension, syncope</p>
<p style="text-indent:-2em;margin-left:2em;">Central nervous system: Abnormality in thinking, agitation, anxiety, ataxia, central nervous system stimulation, confusion, depression, dizziness, drowsiness, hallucination, headache, insomnia, nervousness, nightmares, psychiatric disturbance</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic: Exfoliative dermatitis, skin rash</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Constipation, nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:2em;">Hematologic &amp; oncologic: Megaloblastic anemia</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic: Hepatotoxicity</p>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity: Angioedema, hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:2em;">Local: Injection site reaction</p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular &amp; skeletal: Hyperkinesia, laryngospasm</p>
<p style="text-indent:-2em;margin-left:2em;">Respiratory: Apnea (especially with rapid IV use), hypoventilation, respiratory depression</p>
<p style="text-indent:-2em;margin-left:2em;">Miscellaneous: Fever</p></div>
<div class="block coi drugH1Div" id="F208159"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to barbiturates or any component of the formulation; porphyria.</p></div>
<div class="block war drugH1Div" id="F208140"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory depression: May cause respiratory depression particularly when administered intravenously; use with caution in patients with respiratory disease. Intubation is typically required prior to treatment for seizures or traumatic brain injury (NCS [Brophy 2012]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Depression: Use with caution in patients with depression or suicidal tendencies.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; reduce dose as appropriate. Do not use in patients showing premonitory signs of hepatic coma.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; reduce dose as appropriate.</p>
<p style="text-indent:-2em;margin-left:4em;">• Substance abuse: Use with caution in patients with a history of drug abuse; potential for drug dependency exists. Tolerance, psychological and physical dependence may occur with prolonged use.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Debilitated patients: Use with caution in patients who are debilitated; marked excitement, depression, and confusion may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in older adult patients; marked excitement, depression, and confusion may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric neurotoxicity: In pediatric and neonatal patients &lt;3 years of age and patients in third trimester of pregnancy (ie, times of rapid brain growth and synaptogenesis), the repeated or lengthy exposure to sedatives or anesthetics during surgery/procedures may have detrimental effects on child or fetal brain development and may contribute to various cognitive and behavioral problems. Epidemiological studies in humans have reported various cognitive and behavioral problems, including neurodevelopmental delay (and related diagnoses), learning disabilities, and ADHD. Human clinical data suggest that single, relatively short exposures are not likely to have similar negative effects. No specific anesthetic/sedative has been found to be safer. For elective procedures, risk vs benefits should be evaluated and discussed with parents/caregivers/patients; critical surgeries should not be delayed (FDA 2016).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated with hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Zar 2007). See manufacturer’s labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Acute or chronic pain: Use caution when administering to patients with acute or chronic pain; paradoxical excitement could be induced or important symptoms could be masked.</p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: IV administration: Too rapid IV administration may cause respiratory depression, apnea, laryngospasm, or vasodilation with hypotension.</p>
<p style="text-indent:-2em;margin-left:4em;">• Withdrawal: Antiseizure medications should not be discontinued abruptly because of the possibility of increasing seizure frequency; therapy should be withdrawn gradually to minimize the potential of increased seizure frequency, unless safety concerns require a more rapid withdrawal.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878588"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">In pediatric and neonatal patients &lt;3 years of age and patients in third trimester of pregnancy (ie, times of rapid brain growth and synaptogenesis), the repeated or lengthy exposure to sedatives or anesthetics during surgery/procedures may have detrimental effects on the child's or fetus' brain development and may contribute to various cognitive and behavioral problems; the FDA is requiring warnings be included in the manufacturer's labeling for all general anesthetic/sedative drugs. Multiple animal species studies have shown adverse effects on brain maturation; in juvenile animals, drugs that potentiate GABA activity and/or block NMDA receptors for &gt;3 hours demonstrated widespread neuronal and oligodendrocyte cell loss along with alteration in synaptic morphology and neurogenesis. Epidemiological studies in humans have reported various cognitive and behavioral problems including neurodevelopmental delay (and related diagnoses), learning disabilities, and attention deficit hyperactivity disorder (ADHD). Human clinical data suggest that single, relatively short exposures are not likely to have similar negative effects. Further studies are needed to fully characterize findings and ensure that these findings are not related to underlying conditions or the procedure itself. No specific anesthetic/sedative has been found to be safer. For elective procedures, risk vs benefits should be evaluated and discussed with parents/caregivers/patients; critical surgeries should not be delayed (FDA 2016).</p>
<p style="text-indent:0em;margin-top:2em;">Some dosage forms may contain propylene glycol; in neonates, large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block foc drugH1Div" id="F208152"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nembutal: 50 mg/mL (20 mL [DSC], 50 mL [DSC]) [latex free; contains alcohol, usp, propylene glycol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg/mL (20 mL, 50 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as sodium [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg/mL (20 mL, 50 mL)</p></div>
<div class="block geq drugH1Div" id="F208136"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16570484"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (PENTObarbital Sodium Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg/mL (per mL): $72.62 - $84.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adip drugH1Div" id="F53568131"><span class="drugH1">Additional Information</span>
<p style="text-indent:0em;display:inline">Tolerance to hypnotic effect can occur; taper dose to prevent withdrawal; in pediatric patients, a total cumulative pentobarbital dose &gt;25 mg/kg or duration ≥5 to 7 days have been reported to have a higher probability of withdrawal. To prevent withdrawal in susceptible pediatric patients, the following dosing approach transitioning to PHENobarbital has been described: Discontinue PENTobarbital infusion; 6 hours later, administer half of the PHENobarbital IV loading dose (see table) over 1 hour followed 6 hours later by the remaining half of PHENObarbital loading dose IV (over 1 hour). Begin maintenance PHENobarbital dose 6 hours after loading dose completed; the maintenance PHENobarbital dose should be <sup>1</sup>/<sub>3</sub> of the initial loading dose IV given every 12 hours. Once patient is stabilized, may switch to oral therapy and begin tapering 10% to 20% weekly (Tobias 2000a; Tobias 2000b). <b> Note:</b> This conversion method is based on preliminary data and further studies are needed to confirm the efficacy of this regimen.</p>
<table border="1" frame="border" rules="all">
<colgroup><col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;">PENTobarbital Infusion Rate (mg/kg/hour)</p></th>
<th align="center">
<p style="text-indent:0em;">PHENobarbital IV Loading Dose (mg/kg)</p></th></tr></thead>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">1 to 2</p></td>
<td align="center">
<p style="text-indent:0em;">8</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">2 to 3</p></td>
<td align="center">
<p style="text-indent:0em;">15</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">3 to 4</p></td>
<td align="center">
<p style="text-indent:0em;">20</p></td></tr></tbody></table></div>
<div class="block csi drugH1Div" id="F208202"><span class="drugH1">Controlled Substance</span>
<p style="text-indent:0em;display:inline">C-II</p></div>
<div class="block admp drugH1Div" id="F52613565"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Parenteral:</p>
<p style="text-indent:-2em;margin-left:4em;">IM: May be administered by deep IM; inject into a large muscle. No more than 5 mL should be injected at any one site because of possible tissue irritation.</p>
<p style="text-indent:-2em;margin-left:4em;">IV:</p>
<p style="text-indent:-2em;margin-left:6em;">Intermittent IV injection: Administer undiluted (50 mg/mL) by slow IV injection; infuse over 10 to 30 minutes not to exceed 50 mg/minute; rapid IV injection may cause respiratory depression, apnea, laryngospasm, bronchospasm, and hypotension; loading doses have been infused over 30 to 160 minutes in traumatic brain injury patients to decrease the risk of hypotension and decrease cerebral perfusion pressure (Schaible 1982; Wermeling 1987).</p>
<p style="text-indent:-2em;margin-left:6em;">Continuous IV infusion: Administer at a concentration ≤50 mg/mL via infusion pump; if administering diluted solution monitor for precipitation (Gupta 2001; Sugai 1998). Solution highly alkaline (pH=9.5); care should be taken to avoid extravasation; consider administration using large bore vein (not hand or wrist) or via a running IV line at port farthest from patient's vein.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral: Parenteral solution may be mixed with flavored (eg, cherry) syrup prior to administration to improve palatability (Chung 2000; Mason 2004).</p></div>
<div class="block adm drugH1Div" id="F208156"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Administer by deep IM or slow IV injection.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IM:</b> Inject into a large muscle. No more than 5 mL (250 mg) should be injected at any one site because of possible tissue irritation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Do not exceed 50 mg/minute; IV push doses may be given undiluted. Parenteral solutions are highly alkaline; may be an irritant; avoid extravasation. Avoid intra-arterial injection. Discontinue administration of injection if patient complains of limb pain.</p></div>
<div class="block sts drugH1Div" id="F208168"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 20°C to 25°C (68°F to 77°F). Protect from freezing and avoid excessive heat. When mixed with an acidic solution, precipitate may form; use only clear solution.</p></div>
<div class="block usep drugH1Div" id="F53568307"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Sedation, preanesthetic, short-term treatment of insomnia, and emergency treatment of acute convulsive episodes associated with certain conditions such as status epilepticus, eclampsia, tetanus, cholera, meningitis, and toxic reactions to local anesthetics or strychnine (FDA approved in pediatric patients [age not specified] and adults); has also been used for procedural sedation (parenteral, oral, and rectal), treatment of increased intracranial pressure, and sedation for the mechanically ventilated ICU patient. <b>Note:</b> The American Academy of Sleep Medicine guidelines recommend against the use of barbiturates such as pentobarbital for the management of insomnia in adults (AASM [Schutte-Rodin 2008]). Although FDA approved for seizures associated with local anesthetics, use has been replaced by other agents (eg, fat emulsion) (Weinberg 2012).</p></div>
<div class="block mst drugH1Div" id="F208210"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">PENTobarbital may be confused with PHENobarbital</p>
<p style="text-indent:-2em;margin-left:4em;">Nembutal may be confused with Myambutol</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Pentobarbital is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) due to its high rate of physical dependence, tolerance to sleep benefits, and increased risk of overdose at low dosages (Beers Criteria [AGS 2023]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F208195"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F208145"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: Barbiturates may enhance the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Hyponatremia-Associated Agents may enhance the hyponatremic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxycycline: Barbiturates may decrease the serum concentration of Doxycycline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Griseofulvin: Barbiturates may decrease the serum concentration of Griseofulvin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hemin: Barbiturates may diminish the therapeutic effect of Hemin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mefloquine: May diminish the therapeutic effect of Antiseizure Agents. Mefloquine may decrease the serum concentration of Antiseizure Agents. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of seizures. If antiseizure drugs are being used for another indication, monitor antiseizure drug concentrations and treatment response closely with concurrent use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxyflurane: Barbiturates may enhance the nephrotoxic effect of Methoxyflurane. Barbiturates may increase the metabolism of Methoxyflurane. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoprolol: PENTobarbital may enhance the hypotensive effect of Metoprolol. PENTobarbital may decrease the serum concentration of Metoprolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetroNIDAZOLE (Systemic): May enhance the adverse/toxic effect of Products Containing Propylene Glycol. A disulfiram-like reaction may occur.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyraPONE: Antiseizure Agents may diminish the diagnostic effect of MetyraPONE.  Management: Consider alternatives to the use of the metyrapone test in patients taking antiseizure agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mianserin: May enhance the CNS depressant effect of Barbiturates. Mianserin may diminish the therapeutic effect of Barbiturates. Barbiturates may decrease the serum concentration of Mianserin.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Barbiturates.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ornidazole: May enhance the adverse/toxic effect of Products Containing Propylene Glycol. Specifically, a disulfiram-like reaction may occur.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products.  Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secnidazole: Products Containing Propylene Glycol may enhance the adverse/toxic effect of Secnidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: Barbiturates may decrease the serum concentration of Theophylline Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tricyclic Antidepressants: Barbiturates may increase the metabolism of Tricyclic Antidepressants.  Management: Monitor for decreased efficacy of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. Tricyclic antidepressant dose adjustments are likely required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valproate Products: May increase the serum concentration of Barbiturates. Barbiturates may decrease the serum concentration of Valproate Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Barbiturates may increase the metabolism of Vitamin K Antagonists.  Management: Monitor INR more closely. Anticoagulant dose increases of 30% to 60%  may be needed after a barbiturate is initiated or given at an increased dose. Anticoagulant dose decreases may be needed following barbiturate discontinuation or dose reduction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F10580824"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Barbiturates can be detected in the placenta, fetal liver and fetal brain. Fetal and maternal blood concentrations may be similar following parenteral administration. An increased incidence of fetal abnormalities may occur following maternal use. When used during the third trimester of pregnancy, withdrawal symptoms may occur in the neonate including seizures and hyperirritability; symptoms may be delayed up to 14 days. Use of hypnotic doses during labor does not impair uterine activity; however, use of full anesthetic doses decrease the force and frequency of uterine contractions. Respiratory depression may occur in the newborn when sedative-hypnotic barbiturates are administered to the mother during labor; resuscitation equipment should be available, especially for premature infants.</p></div>
<div class="block mopp drugH1Div" id="F53568300"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Vital signs including blood pressure, respiratory status (including pulse oximetry for moderate sedation), cardiovascular status, CNS status, end tidal CO<sub>2</sub>. Monitor EEG when using pentobarbital to treat status epilepticus or to reduce intracranial pressure (ICP). Monitor ICP and cerebral perfusion pressure (CPP) (CPP = MAP − ICP) when using pentobarbital coma to reduce ICP. Consider monitoring for signs of propylene glycol toxicity (eg, lactic acidosis, acute renal failure, osmolar gap) in patients who require an extended or high-dose continuous infusion of pentobarbital. Periodically monitor renal, hepatic, and hematopoietic function with prolonged therapy. If administering diluted solution, monitor closely for precipitation.</p></div>
<div class="block rerp drugH1Div" id="F53568117"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">Therapeutic:</p>
<p style="text-indent:-2em;margin-left:2em;">Hypnotic: 1 to 5 mcg/mL (SI: 4 to 22 micromoles/L)</p>
<p style="text-indent:-2em;margin-left:2em;">Coma: 20 to 50 mcg/mL (SI: 88 to 221 micromoles/L)</p>
<p style="text-indent:-2em;margin-left:2em;">Toxic: &gt;10 mcg/mL (SI: &gt;44 μmol/L)</p></div>
<div class="block pha drugH1Div" id="F208139"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Barbiturate with sedative, hypnotic, and antiseizure properties. Barbiturates depress the sensory cortex, decrease motor activity, alter cerebellar function, and produce drowsiness, sedation, and hypnosis. In high doses, barbiturates exhibit antiseizure activity; barbiturates produce dose-dependent respiratory depression; reduce brain metabolism and cerebral blood flow in order to decrease intracranial pressure</p></div>
<div class="block phk drugH1Div" id="F208158"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action (Krauss 2006): Children and Adults: Sedation: IM: 10 to 15 minutes; IV: Almost immediate, within 3 to 5 minutes; Oral, Rectal: 15 to 60 minutes </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Duration (Krauss 2006): Children and Adults: Sedation: IM: 1 to 2 hours; IV: 15 to 45 minutes; Oral, Rectal: 1 to 4 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: V<sub>d</sub>: Children: 0.8 L/kg (Schaible 1982); Adults: 1 L/kg (Ehrnebo 1974)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: 45% to 70%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hepatic via hydroxylation and glucuronidation (Wermeling 1985)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Terminal: Children: 26 ± 16 hours (Schaible 1982); Adults: Healthy: 22 hours (average)  (Ehrnebo 1974); Range: 15 to 50 hours; dose dependent</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (&lt;1%, as unchanged drug)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038764"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Pentobarbital</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Entobar</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Pentobarbital</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Pentobarbital</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Pentobarbital</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Nembutal</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18486818">
<a name="18486818"></a>Abend NS and Dlugos DJ. Treatment of refractory status epilepticus: Literature review and a proposed protocol. <i>Pediatr Neurol</i>. 2008;38(6):377-390.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/18486818/pubmed" id="18486818" target="_blank">18486818</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18514819">
<a name="18514819"></a>Abou Khaled KJ and Hirsch LJ, "Updates in the Management of Seizures and Status Epilepticus in Critically Ill Patients," <i>Neurol Clin</i>, 2008, 26(2):385-408.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/18514819/pubmed" id="18514819" target="_blank">18514819</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12847349">
<a name="12847349"></a>Adelson PD, Bratton SL, Carney NA, et al. Guidelines for the acute medical management of severe traumatic brain injury in infants, children, and adolescents. Chapter 13. The use of barbiturates in the control of intracranial hypertension in severe pediatric traumatic brain injury. <i>Pediatr Crit Care Med</i>. 2003;4(3 Suppl):S49-S52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/12847349/pubmed" id="12847349" target="_blank">12847349</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ASHP.1">
<a name="ASHP.1"></a>American Society of Health-System Pharmacists (ASHP). Pediatric continuous infusion standards. Available at https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/Pediatric-Infusion-Standards.ashx. Updated January 2021. Accessed November 15, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17511550">
<a name="17511550"></a>Brain Trauma Foundation, American Association of Neurological Surgeons, Congress of Neurological Surgeons, et al. Guidelines for the management of severe traumatic brain injury. XI. Anesthetics, analgesics, and sedatives. <i>J Neurotrauma</i>. 2007;24 Suppl 1:S71-S76.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/17511550/pubmed" id="17511550" target="_blank">17511550</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10937896">
<a name="10937896"></a>Brain Trauma Foundation, American Association of Neurological Surgeons, and Joint Section on Neurotrauma and Critical Care. Use of barbiturates in the control of intracranial hypertension. <i>J Neurotrauma</i>. 2000;17(6-7):527-530.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/10937896/pubmed" id="10937896" target="_blank">10937896</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22528274">
<a name="22528274"></a>Brophy GM, Bell R, Claassen J, et al; Neurocritical Care Society Status Epilepticus Guideline Writing Committee. Guidelines for the evaluation and management of status epilepticus. <i>Neurocrit Care</i>. 2012;17(1):3-23.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/22528274/pubmed" id="22528274" target="_blank">22528274</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27654000">
<a name="27654000"></a>Carney N, Totten AM, O'Reilly C, et al. Guidelines for the management of severe traumatic brain injury, fourth edition. <i>Neurosurgery</i>. 2017;80(1):6-15.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/27654000/pubmed" id="27654000" target="_blank">27654000</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14593936">
<a name="14593936"></a>Censullo JL, Sebastian S. Pentobarbital sodium coma for refractory intracranial hypertension. <i>J Neurosci Nurs</i>. 2003;35(5):252-262.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/14593936/pubmed" id="14593936" target="_blank">14593936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10836598">
<a name="10836598"></a>Chung T, Hoffer FA, Connor L, et al. The use of oral pentobarbital sodium (nembutal) versus chloral hydrate in infants undergoing CT and MR imaging – a pilot study. <i>Pediatr Radiol</i>. 2000;30:332-335.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/10836598/pubmed" id="10836598" target="_blank">10836598</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Coté CJ, Lerman J, Anderson BJ, eds. <i>A Practice of Anesthesia Children</i>. 5th ed. Philadelphia, PA: Elsevier Saunders; 2013.</div>
</li>
<li>
<div class="reference">
                  Coté CJ, Lerman J, Anderson B, eds. <i>A Practice of Anesthesia for Infants and Children</i>. 6th ed. Elsevier; 2019:1122.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4853598">
<a name="4853598"></a>Ehrnebo M, “Pharmacokinetics and Distribution Properties Of Pentobarbital in Humans Following Oral and Intravenous Administration,”<i>J Pharm Sci</i>, 1974, 63(7):1114-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/4853598/pubmed" id="4853598" target="_blank">4853598</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3288723">
<a name="3288723"></a>Eisenberg HM, Frankowski RF, Contant CF, Marshall LF, Walker MD. High-dose barbiturate control of elevated intracranial pressure in patients with severe head injury. <i>J Neurosurg</i>. 1988;69(1):15-23.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/3288723/pubmed" id="3288723" target="_blank">3288723</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3691007">
<a name="3691007"></a>Fischer JH and Raineri DL, “Pentobarbital Anesthesia for Status Epilepticus,” <i>Clin Pharm</i>, 1987, 6(8):601-2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/3691007/pubmed" id="3691007" target="_blank">3691007</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Food and Drug Administration. FDA Drug Safety Communication: FDA review results in new warnings about using general anesthetics and sedation drugs in young children and pregnant women. <a href="https://www.fda.gov/Drugs/DrugSafety/ucm532356.htm" target="_blank">https://www.fda.gov/Drugs/DrugSafety/ucm532356.htm</a>. Published December 14, 2016. Accessed May 26, 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26900382">
<a name="26900382"></a>Glauser T, Shinnar S, Gloss D, et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the Guideline Committee of the American Epilepsy Society. <i>Epilepsy Curr</i>. 2016;16(1):48-61.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/26900382/pubmed" id="26900382" target="_blank">26900382</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Gupta VD. Stability of pentobarbital sodium after reconstitution in 0.9% sodium chloride injection and repackaging in glass and polypropylene syringes. <i>International Journal of Pharmaceutical Compounding.</i> 2001, 5(6): 482-484.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10328273">
<a name="10328273"></a>Holmes GL and Riviello JJ. Midazolam and pentobarbital for refractory status epilepticus. <i>Pediatr Neurol</i>. 1999;20(4):259-264.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/10328273/pubmed" id="10328273" target="_blank">10328273</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11587876">
<a name="11587876"></a>Kim SJ, Lee DY, and Kim JS. Neurologic outcomes of pediatric epileptic patients with pentobarbital coma. <i>Pediatr Neurol</i>. 2001;25(3):217-220.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/11587876/pubmed" id="11587876" target="_blank">11587876</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30822776">
<a name="30822776"></a>Kochanek PM, Tasker RC, Carney N, et al. Guidelines for the management of pediatric severe traumatic brain injury, third edition: update of the Brain Trauma Foundation guidelines, executive summary. <i>Neurosurgery</i>. 2019;84(6):1169-1178. doi:10.1093/neuros/nyz051<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/30822776/pubmed" id="30822776" target="_blank">30822776</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16517277">
<a name="16517277"></a>Krauss B and Green SM. Procedural sedation and analgesia in children. <i>Lancet</i>. 2006;367(9512):766-780.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/16517277/pubmed" id="16517277" target="_blank">16517277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15516603">
<a name="15516603"></a>Mason KP, Zurakowski D, Connor L, et al. Infant sedation for MR imaging and CT: Oral versus intravenous pentobarbital. <i>Radiology</i>. 2004;233(3):723-728.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/15516603/pubmed" id="15516603" target="_blank">15516603</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12528780">
<a name="12528780"></a>Mazzola CA and Adelson PD. Critical care management of head trauma in children. <i>Crit Care Med</i>. 2002;30(11 Suppl):S393-S401.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/12528780/pubmed" id="12528780" target="_blank">12528780</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18698010">
<a name="18698010"></a>Miller MA, Forni A, and Yogaratnam D. Propylene glycol-induced lactic acidosis in a patient receiving continuous infusion pentobarbital. <i>Ann Pharmacother</i>. 2008;42(10):1502-1506.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/18698010/pubmed" id="18698010" target="_blank">18698010</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19218022">
<a name="19218022"></a>Millikan D, Rice B, and Silbergleit R, "Emergency Treatment of Status Epilepticus: Current Thinking," <i>Emerg Med Clin North Am</i>, 2009, 27(1):101-13, ix.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/19218022/pubmed" id="19218022" target="_blank">19218022</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25147175">
<a name="25147175"></a>Murray KL, Wright D, Laxton B, Miller KM, Meyers J, Englebright J. Implementation of standardized pediatric i.v. medication concentrations. <i>Am J Health Syst Pharm</i>. 2014;71(17):1500-1508.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/25147175/pubmed" id="25147175" target="_blank">25147175</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Nembutol (pentobarbital) [prescribing information]. Lake Forest, IL: Akorn Inc; February 2020.</div>
</li>
<li>
<div class="reference">
                  Nembutal (pentobarbital sodium, solution) [prescribing information]. Lake Forest, IL: Akorn; February 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8233681">
<a name="8233681"></a>Pereira JK, Burrows PE, Richards HM, et al, “Comparison of Sedation Regimens for Pediatric Outpatient CT,” <i>Pediatr Radiol</i>, 1993, 23(5):341-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/8233681/pubmed" id="8233681" target="_blank">8233681</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22926232">
<a name="22926232"></a>Pillai U, Hothi JC, Bhat ZY. Severe propylene glycol toxicity secondary to use of anti-epileptics. <i>Am J Ther</i>. 2014;21(4):e106-e109.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/22926232/pubmed" id="22926232" target="_blank">22926232</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18514825">
<a name="18514825"></a>Rangel-Castilla L, Gopinath S, and Robertson CS. Management of intracranial hypertension. <i>Neurol Clin</i>. 2008;26(2):521-541.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/18514825/pubmed" id="18514825" target="_blank">18514825</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24420913">
<a name="24420913"></a>Reynolds PM, MacLaren R, Mueller SW, Fish DN, Kiser TH. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. <i>Pharmacotherapy</i>. 2014;34(6):617-632. doi: 10.1002/phar.1396.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/24420913/pubmed" id="24420913" target="_blank">24420913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27998379">
<a name="27998379"></a>Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. <i>J Clin Sleep Med</i>. 2017;13(2):307-349. doi: 10.5664/jcsm.6470.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/27998379/pubmed" id="27998379" target="_blank">27998379</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7062221">
<a name="7062221"></a>Schaible DH, Cupit GC, Swedlow DB, et al. High-dose pentobarbital pharmacokinetics in hypothermic brain-injured children. <i>J Pediatr</i>. 1982;100(4):655-660.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/7062221/pubmed" id="7062221" target="_blank">7062221</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18853708">
<a name="18853708"></a>Schutte-Rodin S, Broch L, Buysse D, Dorsey C, Sateia M. Clinical guideline for the evaluation and management of chronic insomnia in adults. <i>J Clin Sleep Med</i>. 2008;4(5):487-504.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/18853708/pubmed" id="18853708" target="_blank">18853708</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26673840">
<a name="26673840"></a>Shein SL, Ferguson NM, Kochanek PM, et al. Effectiveness of pharmacological therapies for intracranial hypertension in children with severe traumatic brain injury--results from an automated data collection system time-synched to drug administration. <i>Pediatr Crit Care Med</i>. 2016;17(3):236-245. doi:10.1097/PCC.0000000000000610<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/26673840/pubmed" id="26673840" target="_blank">26673840</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Sugai K, Sasaki M, Hanaoka S, et al. Practice of pentobarbital therapy in convulsive status epilepticus in children with epilepsy. <i>Epilepsia</i>. 1998; 19(S5):83. Available at http://onlinelibrary.wiley.com/doi/10.1111/j.1528-1157.1998.tb01980.x/abstract
                  </div>
</li>
<li>
<div class="reference">
                  Tobias JD. Pentobarbital for sedation during mechanical ventilation in the pediatric ICU patient. <i>J Intensive Care Med</i>. 2000b;15:115-120.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10890677">
<a name="10890677"></a>Tobias JD. Tolerance, withdrawal, and physical dependency after long-term sedation and analgesia of children in the pediatric intensive care unit. <i>Crit Care Med</i>. 2000a;28(6):2122-2132.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/10890677/pubmed" id="10890677" target="_blank">10890677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7886524">
<a name="7886524"></a>Tobias JD, Deshpande JK, Pietsch JB, et al. Pentobarbital sedation for patients in the pediatric intensive care unit. <i>South Med J</i>. 1995;88(3):290-294.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/7886524/pubmed" id="7886524" target="_blank">7886524</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7294399">
<a name="7294399"></a>Walker SE, Iazzetta J. Compatibility and stability of pentobarbital in infusions. <i>Anesthesiology</i>. 1981;55(4):487-489.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/7294399/pubmed" id="7294399" target="_blank">7294399</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22627464">
<a name="22627464"></a>Weinberg GL. Lipid emulsion infusion: resuscitation for local anesthetic and other drug overdose. <i>Anesthesiology</i>. 2012;117(1):180-187. doi:10.1097/ALN.0b013e31825ad8de<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/22627464/pubmed" id="22627464" target="_blank">22627464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3582175">
<a name="3582175"></a>Wermeling DP, Blouin RA, Porter WH, Rapp RP, Tibbs PA. Pentobarbital pharmacokinetics in patients with severe head injury.<i> Drug Intell Clin Pharm</i>. 1987;21(5):459-463.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/3582175/pubmed" id="3582175" target="_blank">3582175</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4082247">
<a name="4082247"></a>Wermeling D, Record K, Bell R, et al. Hemodialysis clearance of pentobarbital during continuous infusion. <i>Ther Drug Monit</i>. 1985;7(4):485-487.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/4082247/pubmed" id="4082247" target="_blank">4082247</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8492944">
<a name="8492944"></a>Yaffe K and Lowenstein DH, "Prognostic Factors of Pentobarbital Therapy for Refractory Generalized Status Epilepticus," <i>Neurology</i>, 1993, 43(5):895-900.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/8492944/pubmed" id="8492944" target="_blank">8492944</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15484178">
<a name="15484178"></a>Yanay O, Brogan TV, and Martin LD. Continuous pentobarbital infusion in children is associated with high rates of complications. <i>J Crit Care</i>. 2004;19(3):174-178.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/15484178/pubmed" id="15484178" target="_blank">15484178</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17555487">
<a name="17555487"></a>Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219. doi: 10.1111/j.1525-139X.2007.00280.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentobarbital-pediatric-drug-information/abstract-text/17555487/pubmed" id="17555487" target="_blank">17555487</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12693 Version 323.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
